1. Home
  2. ADPT vs NSIT Comparison

ADPT vs NSIT Comparison

Compare ADPT & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$27.73

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Insight Enterprises Inc.

NSIT

Insight Enterprises Inc.

N/A

Current Price

$150.97

Market Cap

5.1B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
NSIT
Founded
2009
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
5.1B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
ADPT
NSIT
Price
$27.73
$150.97
Analyst Decision
Strong Buy
Hold
Analyst Count
8
4
Target Price
$33.86
★ $177.50
AVG Volume (30 Days)
★ 2.1M
463.7K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.89
N/A
EPS
N/A
★ 4.28
Revenue
$276,976,000.00
★ $8,247,180,000.00
Revenue This Year
$10.85
$12.22
Revenue Next Year
$21.60
$4.75
P/E Ratio
★ N/A
$37.49
Revenue Growth
★ 54.77
N/A
52 Week Low
$12.00
$63.62
52 Week High
$32.21
$182.12

Technical Indicators

Market Signals
Indicator
ADPT
NSIT
Relative Strength Index (RSI) 49.06 40.17
Support Level $24.02 $150.99
Resistance Level $29.92 $163.53
Average True Range (ATR) 1.71 8.85
MACD -0.09 -1.83
Stochastic Oscillator 31.91 2.65

Price Performance

Historical Comparison
ADPT
NSIT

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About NSIT Insight Enterprises Inc.

Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.

Share on Social Networks: